These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27621009)

  • 1. The impact of postoperative adjuvant chemotherapy on the development of nonalcoholic fatty liver disease after pancreatoduodenectomy.
    Nishikawa M; Aosasa S; Moriya T; Noro T; Hase K; Yamamoto J
    J Surg Res; 2016 Sep; 205(1):127-35. PubMed ID: 27621009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease after pancreatoduodenectomy is closely associated with postoperative pancreatic exocrine insufficiency.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sasaki H; Okano K; Sueda T
    J Surg Oncol; 2014 Nov; 110(6):720-6. PubMed ID: 24965234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients undergoing pancreaticoduodenectomy.
    Okabe H; Yamashita YI; Inoue R; Kinoshita S; Itoyama R; Yusa T; Nakao Y; Yamao T; Umezaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Hayashi H; Imai K; Chikamoto A; Baba H
    Surg Today; 2020 Feb; 50(2):193-199. PubMed ID: 31463596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative Computed Tomography Assessments of the Pancreas Predict Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy.
    Ohgi K; Okamura Y; Yamamoto Y; Ashida R; Ito T; Sugiura T; Aramaki T; Uesaka K
    Medicine (Baltimore); 2016 Feb; 95(6):e2535. PubMed ID: 26871772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of predictive factors in patients with nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Ito Y; Kenmochi T; Shibutani S; Egawa T; Hayashi S; Nagashima A; Kitagawa Y
    Am Surg; 2014 May; 80(5):500-4. PubMed ID: 24887731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical impact of the remnant pancreatic volume and infectious complications on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Sato R; Kishiwada M; Kuriyama N; Azumi Y; Mizuno S; Usui M; Sakurai H; Tabata M; Yamada T; Isaji S
    J Hepatobiliary Pancreat Sci; 2014 Aug; 21(8):562-72. PubMed ID: 24824077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors that predict the occurrence of and recovery from non-alcoholic fatty liver disease after pancreatoduodenectomy.
    Sato T; Matsuo Y; Shiga K; Morimoto M; Miyai H; Takeyama H
    Surgery; 2016 Aug; 160(2):318-30. PubMed ID: 27211602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer.
    Kouzu K; Tsujimoto H; Nishikawa M; Harada M; Sugihara T; Nagata H; Hiraki S; Yaguchi Y; Takahata R; Nomura S; Ito N; Ishibashi Y; Itazaki Y; Tsuchiya S; Hase K; Kishi Y; Ueno H
    Gastric Cancer; 2020 Mar; 23(2):356-362. PubMed ID: 31555950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system.
    Kato H; Isaji S; Azumi Y; Kishiwada M; Hamada T; Mizuno S; Usui M; Sakurai H; Tabata M
    J Hepatobiliary Pancreat Sci; 2010 May; 17(3):296-304. PubMed ID: 19809782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated functional remnant pancreatic volume predicts nonalcoholic fatty liver disease after pancreaticoduodenectomy: use of computed tomography attenuation value of the pancreas.
    Maehira H; Iida H; Maekawa T; Yasukawa D; Mori H; Takebayashi K; Kaida S; Miyake T; Matsubara A; Tani M
    HPB (Oxford); 2021 May; 23(5):802-811. PubMed ID: 33046368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Nagai M; Sho M; Satoi S; Toyokawa H; Akahori T; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kinoshita S; Nishiwada S; Ikeda N; Kwon AH; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2014 Mar; 21(3):186-92. PubMed ID: 23798362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancrelipase with branched-chain amino acids for preventing nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Yamazaki S; Takayama T; Higaki T; Moriguchi M; Yoshida N; Miyazaki T; Teshima Y
    J Gastroenterol; 2016 Jan; 51(1):55-62. PubMed ID: 25904096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial.
    Satoi S; Sho M; Yanagimoto H; Yamamoto T; Akahori T; Kinoshita S; Nagai M; Hirooka S; Yamaki S; Nishiwada S; Ryota H; Ikeda N; Nakajima Y; Kon M
    J Hepatobiliary Pancreat Sci; 2016 Mar; 23(3):167-73. PubMed ID: 26748629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial.
    Yasukawa K; Shimizu A; Yokoyama T; Kubota K; Notake T; Seki H; Kobayashi A; Soejima Y
    J Am Coll Surg; 2020 Dec; 231(6):658-669. PubMed ID: 32927075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain after orthotopic liver transplantation: is nonalcoholic fatty liver disease cirrhosis a risk factor for greater weight gain?
    Kouz J; Vincent C; Leong A; Dorais M; Räkel A
    Liver Transpl; 2014 Oct; 20(10):1266-74. PubMed ID: 25044355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors of developing nonalcoholic fatty liver disease after pancreatic resection: a systematic review and meta-analysis.
    Sugumar K; Naik L; Hue JJ; Ammori JB; Hardacre JM; Ocuin LM; Winter JM
    J Gastrointest Surg; 2024 Jun; 28(6):983-992. PubMed ID: 38552899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk factors of newly developed nonalcoholic fatty liver disease after pancreaticoduodenectomy].
    Yang YF; Cai ZH; Fu X; Zhang J; Qiu YD; Mao L
    Zhonghua Wai Ke Za Zhi; 2022 Jan; 60(1):46-51. PubMed ID: 34954946
    [No Abstract]   [Full Text] [Related]  

  • 19. New onset non-alcoholic fatty liver disease after resection of pancreatic neuroendocrine tumors.
    Mackay TM; Genç CG; Takkenberg RB; Besselink MG; Somers I; Nieveen van Dijkum EJM
    J Surg Oncol; 2018 Jun; 117(7):1548-1555. PubMed ID: 29572825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors of nonalcoholic fatty liver disease after total pancreatectomy: A first multicenter prospective study in Japan.
    Kato H; Kamei K; Suto H; Misawa T; Unno M; Nitta H; Satoi S; Kawabata Y; Ohtsuka M; Rikiyama T; Sudo T; Matsumoto I; Okano K; Suzuki Y; Sata N; Isaji S; Sugiyama M; Takeyama Y
    J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):428-438. PubMed ID: 34863034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.